Yeşilay’ın 5. Sağlıklı Fikirler Kısa Film Yarışması’nın kazananları belli oldu

Yeşilay’ın 5. Sağlıklı Fikirler Kısa Film Yarışması’nın kazananları belli oldu

Yeşilay’ın organize ettiği 5. Sağlıklı Fikirler Kısa Sinema Yarışması’nın kazananları, Yeşilay Genel Lide
Ana Sayfa Sağlık 26 Haziran 2021 50 Görüntüleme

HER2-positive cancer clinical trials

HER2 cancer refers to any tumor that tests positive for the presence of the human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. Two of the most common cancers that are positive for the HER2 proteins are stomach (gastric) cancer and breast cancer. Nearly one in three stomach cancer cases are HER2-positive. One in four breast cancer cases are HER2-positive. Other cancer types have been positive for HER2 including bladder, pancreatic, ovarian cancer, and more.

The prognosis of HER2-positive tumors tends to be somewhat poorer than for HER2-negative tumors, but the widespread adoption of HER2 targeted therapies is making a difference in survival rates, especially for HER2 breast cancer. Clinical trials provide cancer patients access to targeted therapies for HER2 cancers. Clinical Trial Matching tools using Artificial-Intelligence engines can quickly match HER2-positive cancer patients to clinical trials based on many factors such as location, stage of disease, and medical history. The Clinical Trial Matching System (CTMS) from Massive Bio gives personalized matches to patients of all cancer types.

Hibya Haber Ajansı

Yorumlar (Yorum Yapılmamış)

Yazı hakkında görüşlerinizi belirtmek istermisiniz?

Dikkat! Suç teşkil edecek, yasadışı, tehditkar, rahatsız edici, hakaret ve küfür içeren, aşağılayıcı, küçük düşürücü, kaba, pornografik, ahlaka aykırı, kişilik haklarına zarar verici ya da benzeri niteliklerde içeriklerden doğan her türlü mali, hukuki, cezai, idari sorumluluk içeriği gönderen Üye/Üyeler’e aittir.